An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR

Cancer Letters

Volumn 253, Issue 2, 2007, Pages 236-248

  Hou, Guiqin ^a   Xue, Lexun ^a   Lu, Zhaoming ^a   Fan, Tianli ^a   Tian, Fang ^a   Xue, Yanli ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Apoptosis; Esophageal squamous cell carcinoma; mTOR; p70S6K; Rapamycin; siRNA

Indexed keywords

COMPLEMENTARY DNA; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; RAPAMYCIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSFECTION; UP-REGULATION;

EID: 34347331090     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.01.026     Document Type: Article

References (39)

1. Pisani P., Parkin D.M., Bray F., and Forlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83 (1999) 18-29
2. Montesano R., Hollstein M., and Hainant P. Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int. J. Cancer 69 (1996) 225-235
3. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
4. Han S., Khuri F.R., and Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signaling pathway. Cancer Res. 66 (2006) 315-323
5. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature 441 (2006) 424-430
6. Xu G., Zhang W., Bertramp P., Zheng X.F., and Mcloeod H. Pharmacogenomic profiling of the PI3K/PTEN -AKT/mTOR pathway in common human tumors. Int. J. Oncol. 24 (2004) 893-900
7. van der Hage J.A., van den Broek L.J., Legrand C., Clahsen P.C., Bosch C.J., Robanus-Maandaq E.C., et al. Overexpression of p70S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative prememopausal early breast cancer patients. Br. J. Cancer 90 (2004) 1543-1550
8. Sahin F., Kannangai R., Adegbola O., Wang J., Su G., and Torbenson M. mTOR and p70S6 kinase expression in primary liner Neoplasms. Clin. Cancer Res. 10 (2004) 8421-8425
9. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res. 65 (2005) 9953-9961
10. Beevers C.S., Li F., Liu L., and Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int. J. Cancer 119 (2006) 757-764
11. Liu L., Li F., Cardelli J.A., Martin K.A., Blenis J., and Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4EBP1 pathways. Oncogene 25 (2006) 7029-7040
12. Sugatani T., and Hruska K.A. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J. Biol. Chem. 280 (2005) 3583-3589
13. Morgensztern D., and Mcleod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16 (2005) 797-803
14. Meng Q., Xia C., Fang J., Rojanasakul Y., and Jiang B.H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell. Signal. 18 (2006) 2262-2271
15. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16 (2004) 564-575
16. Rao R.D., Buckner J.C., and Sarkaria J.N. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr. Cancer Drug Targets 4 (2004) 621-635
17. Carraway H., and Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 6 (2004) 219-224
18. Fingar D.C., and Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23 (2004) 3151-3171
19. Bjornsti M.A., and Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4 (2004) 335-348
20. Chan S. Targeting the mammalian target of rapamycin (mTOR); a new approach to treating cancer. Br. J. Cancer 91 (2004) 1420-1424
21. Georgakis G.V., and Younes A. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Anticancer Ther. 6 (2006) 131-140
22. Dudkin L., Dilling M.B., Cheshire P.J., Harwood F.C., Hollinqshead M., Arbuck S.G., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7 (2001) 1758-1764
23. Asano T., Yao Y., Zhu J., Li D., Abbruzzese J.L., and Reddy S.A. The rapamycin anolog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem. Biophys. Res. Commun. 331 (2005) 295-302
24. Atkins M.B., Hidalgo M., Stadler W.M., Loqan T.F., Dutcher J.P., Hudes G.R., et al. Randomized Phase II study of multiple does levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomas. J. Clin. Oncol. 22 (2004) 909-918
25. Tian F., Zang W.D., Hou W.H., Liu H.T., and Xue L.X. Nuclear factor-kB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA. Acta Biochim. Biophys. Sin. 38 (2006) 318-326
26. Momota H., Nerio E., and Holland E.C. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res. 65 (2005) 7429-7435
27. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (2006) 1500-1508
28. deGraffenried L.A., Fulcher L., Friedrichs W.E., Grunwald V., Ray R.B., and Hidalqo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of PI3 kinase/Akt pathway. Ann. Oncol. 15 (2004) 1510-1516
29. Feng Z., Zhang H., Levine A.J., and Jin S. The coordinate regulation of the p53 and mTOR pathway in cells. Proc. Natl. Acad. Sci. USA 102 (2005) 8204-8209
30. Fingar D.C., Richardson C.J., Tee A.R., Cheathan L., Tsou C., and Blenis J. mTOR controls cell cycle progression through its cell growth effector S6K1 and 4EBP1/eukaryotic translation initiation factor 4E. Mol. Cell Biol. 24 (2004) 200-216
31. Hahn-Windgassen A., Nogueira V., Chen C.C., Skeen J.E., Sonenberq N., and Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 280 (2005) 32081-32089
32. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 17 (2006) 487-494
33. Hu L., Hofmann J., Lu Y., Mills G.B., and Jaffe R.B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in vitro and in vivo ovarian cancer models. Cancer Res. 62 (2002) 1087-1092
34. Kim J.E., and Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc. Natl. Acad. Sci. USA 97 (2000) 14340-14345
35. Martin D.E., and Hall M.N. The expanding TOR signaling network. Curr. Opin. Cell Biol. 17 (2005) 158-166
36. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., and Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005) 7052-7058
37. Treeck O., Wackwitz B., Haus U., and Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gyn. Oncol. 102 (2006) 292-299
38. deGraffenried L.A., Friedrichs W.E., Russel D.H., Donzis E.J., Middleton A.K., Silva J.M., et al. Inhibition of mTOR activity restores tamoxifen response in brease cancer cells with aberrant Akt activity. Clin. Cancer Res. 10 (2004) 8059-8067
39. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498